glp 1 parkinson's disease Are we measuring the wrong primary outcome for GLP-1 drugs for Parkinson's? Spoiler alert: the pooled data suggests we should pivot away from a motor outcome. Should we think cognitive, autonomic, sleep How a 'blockbuster' treatment for

Because that description could easily match insulin, but its also a perfect match for another hormone: GLP-1

An intramuscular injection is absorbed faster because the muscle tissue has more blood supply

Description L-Carnitine Metabolic Support Injection Fat Metabolism & Energy Formula This L-Carnitine metabolic support injection delivers an injectable L-Carnitine solution used to support fat metabolism, energy production, and muscle function

(5) R C Rosen, L E Diamond, D C Earle, et al (2004) Evaluation of the safety, pharmacokinetics and pharmacodynamic effects of subcutaneously administered PT-141, a melanocortin receptor agonist, in healthy male subjects and in patients with an inadequate response to Viagra International Journal of Impotence Research, volume 16, pages 135142 (2004)

The more relevant research question is whether triple receptor agonism (GIP + GLP-1 + glucagon) combining elements of both approaches could outperform either dual agonist